Natco Pharma Ltd (BOM:524816) reports its highest ever revenue and profits, while projecting a dip in FY26 due to geopolitical and market pressures.

Natco Pharma anticipates revenue and profit decline in FY26 due to geopolitical uncertainties and increased R&D expenses.

While several companies are set to announce their fourth quarter results for the financial year 2024-25, here is a date-wise list of some important companies announcing their results in the week ...

Natco Pharma share price: Shares of Natco Pharma tumbled 19.86 per cent to hit a low of Rs 975. The stock saw high trading volume on BSE today.

This pharma stock tanks 20 per cent even as markets trade higher - Here's why NATCO Pharma share price: NATCO Pharma Ltd has reported a 37.75 per cent decline in consolidated net profit.

Natco Pharma Ltd shares tanked during the early trading session on Thursday, February 13, 2025, after it announced weak third quarter financial results.

Shares of NATCO Pharma Ltd on Thursday slumped 20 per cent after the firm reported a 37.75 per cent decline in consolidated net profit in the December quarter. The stock tanked 19.86 per cent to ...

Get all latest & breaking news on Aurobindo Pharma. Watch videos, top stories and articles on Aurobindo Pharma at moneycontrol.com.

After a stellar FY24 performance, Natco Pharma’s stock has taken a hit. What’s next for the company as it faces crucial challenges in the US generics market and beyond?

Natco Pharma Ltd (BOM:524816) reports a 35.3% revenue increase and 83% profit growth, while navigating future market uncertainties and regulatory challenges.

Generic drugmaker Natco Pharma consolidated net profit surged 83% to ₹676.5 crore for the quarter ended September, from ₹369 crore a year earlier, on the back of a robust growth in ...